“BiolineRx announced long-term follow-up data from the phase 2a study of BL-8040 (CXCR4 antagonist) in relapsed/refractory acute myeloid leukemia (r/ r AML) demonstrating improved overall survival (OS).”,” the firm’s analyst commented.
A number of other research firms have also issued reports on BLRX. Zacks Investment Research raised Bioline RX from a hold rating to a buy rating and set a $1.25 price target on the stock in a research report on Tuesday, October 3rd. HC Wainwright set a $4.00 price target on Bioline RX and gave the company a buy rating in a research report on Wednesday, August 9th. Roth Capital set a $3.00 price target on Bioline RX and gave the company a buy rating in a research report on Wednesday, August 9th. Oppenheimer set a $3.00 price target on Bioline RX and gave the company a buy rating in a research report on Wednesday, October 18th. Finally, ValuEngine raised Bioline RX from a strong sell rating to a sell rating in a research report on Thursday, November 30th. Two research analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Bioline RX presently has an average rating of Hold and a consensus price target of $2.88.
Shares of Bioline RX (NASDAQ BLRX) opened at $1.09 on Monday. Bioline RX has a 12-month low of $0.80 and a 12-month high of $1.38.
An institutional investor recently bought a new position in Bioline RX stock. Renaissance Technologies LLC acquired a new stake in Bioline RX Ltd (NASDAQ:BLRX) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 131,480 shares of the biotechnology company’s stock, valued at approximately $126,000. Renaissance Technologies LLC owned about 0.21% of Bioline RX as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 37.21% of the company’s stock.
WARNING: “Maxim Group Analysts Give Bioline RX (BLRX) a $3.00 Price Target” was originally reported by Stock Observer and is owned by of Stock Observer. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.thestockobserver.com/2017/12/07/maxim-group-analysts-give-bioline-rx-blrx-a-3-00-price-target.html.
Bioline RX Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for Bioline RX Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioline RX Ltd and related companies with MarketBeat.com's FREE daily email newsletter.